BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 12208721)

  • 1. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.
    Smith JR; Rosenbaum JT; Wilson DJ; Doolittle ND; Siegal T; Neuwelt EA; Pe'er J
    Ophthalmology; 2002 Sep; 109(9):1709-16. PubMed ID: 12208721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma.
    Zhou N; Xu X; Liu Y; Wang Y; Wei W
    Eye (Lond); 2022 Jul; 36(7):1448-1455. PubMed ID: 34211136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma.
    Fishburne BC; Wilson DJ; Rosenbaum JT; Neuwelt EA
    Arch Ophthalmol; 1997 Sep; 115(9):1152-6. PubMed ID: 9298056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
    Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
    Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Asian patient with intraocular lymphoma treated by intravitreal methotrexate.
    Wang JK; Yang CM; Lin CP; Shan YD; Lo AY; Tien HF
    Jpn J Ophthalmol; 2006; 50(5):474-478. PubMed ID: 17013703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of primary intraocular lymphoma with intravitreal methotrexate.
    Sou R; Ohguro N; Maeda T; Saishin Y; Tano Y
    Jpn J Ophthalmol; 2008; 52(3):167-174. PubMed ID: 18661266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients.
    Zhou X; Zhou X; Shi H; Lai J; Wang Q; Li Y; Chen K; Li Q; Zhou Q; Cao X; Chen B; Xiao J
    BMC Ophthalmol; 2020 May; 20(1):189. PubMed ID: 32397978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.
    Zhuang L; Lai J; Chen K; Ding T; Yuan Y; Ma Y; Kang H; Lin Z; Fan N; Ma J; Zeng Q; Xu X; Wang Q; Chen B
    Oncol Rep; 2019 Jan; 41(1):397-404. PubMed ID: 30320386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravitreal chemotherapy for intraocular lymphoma].
    Helbig H; Cerny T; de Smet MD
    Ophthalmologe; 2003 Feb; 100(2):145-9. PubMed ID: 12589460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption.
    Vicuna-Kojchen J; Frenkel S; Siegal T; Shalom E; Chowers I; Pe'er J
    Br J Ophthalmol; 2008 Feb; 92(2):231-5. PubMed ID: 18227203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal methotrexate injections for intraocular involvement in primary central nervous system lymphoma.
    Tourville E; Tardif Y
    Can J Ophthalmol; 2003 Dec; 38(7):598-601. PubMed ID: 14740803
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience.
    Habot-Wilner Z; Frenkel S; Pe'er J
    Br J Haematol; 2021 Jul; 194(1):92-100. PubMed ID: 33900619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of non Hodgkin's intraocular lymphoma with intravitreal methotrexate.
    de Smet MD
    Bull Soc Belge Ophtalmol; 2001; (279):91-5. PubMed ID: 11344720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eyewash with balanced salt solution after intravitreal methotrexate injection in a case of vitreoretinal lymphoma: a simple but effective way to prevent ocular surface toxicity.
    Moharana B; Parija S; Palanisamy S; Mishra P
    BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37474142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corneal epithelial toxicity with intravitreal methotrexate in a case of B-cell lymphoma with ocular involvement.
    Sahay P; Maharana PK; Temkar S; Chawla R
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30150351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular chemotherapy for vitreoretinal lymphoma: A review.
    Kvopka M; Lake SR; Smith JR
    Clin Exp Ophthalmol; 2020 Mar; 48(2):240-248. PubMed ID: 31680408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of intraocular lymphoma having retinal adverse events associated with intravitreal methotrexate].
    Kuroiwa N; Abematsu N; Matsuo Y; Nakao K; Sakamoto T
    Nippon Ganka Gakkai Zasshi; 2011 Jul; 115(7):611-6. PubMed ID: 21815491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
    Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
    Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of intraocular methotrexate in silicone-filled eyes.
    Hardwig PW; Pulido JS; Bakri SJ
    Retina; 2008 Oct; 28(8):1082-6. PubMed ID: 18779714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma.
    Hardwig PW; Pulido JS; Erie JC; Baratz KH; Buettner H
    Am J Ophthalmol; 2006 Nov; 142(5):883-5. PubMed ID: 17056381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.